{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:31:15Z","timestamp":1790008275521,"version":"4.0.1"},"reference-count":43,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T00:00:00Z","timestamp":1569715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>An indirect consequence of the improved long-term survival seen in patients with breast cancer (BC) is the increased risk of hematologic malignant neoplasms (HM). This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin\u2019s lymphoma or non-Hodgkin\u2019s lymphoma (HL\/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL\/LL). Analyses were censored at HM occurrence, death, loss to follow up, or December 2017. The risk of each type of HM was compared according to the initial postoperative treatment of breast cancer. Of a total of 324,056 BC survivors, 15.5% underwent surgery only, 46.7% received radiotherapy after surgery, 4.3% received chemotherapy after surgery, and 33.5% received all three modalities. Overall, 2236 cases of hematologic malignancies occurred. Compared to the surgery alone group, AML was significantly increased after surgery plus radiation (aHR, 1.5; 95% CI, 1.0\u20132.1), surgery plus chemotherapy (aHR, 2.1; 95% CI, 1.2\u20133.6) and all modalities (aHR, 3.3; 95% CI, 2.3\u20134.7). MDS was significantly increased after surgery plus chemotherapy (aHR, 1.7; 95% CI, 1.1\u20132.5) or after all modalities (aHR, 1.4; 95% CI, 1.1\u20131.8). HL\/NHL were significantly increased only in the radiotherapy and surgery group (aHR, 1.3; 95% CI, 1.0\u20131.6). A nonsignificant increase of ALL\/LL (aHR, 1.8; 95% CI, 0.6\u20133.5) was noted after chemotherapy and with all three modalities (aHR, 1.4; 95% CI, 0.7\u20132.8). Our population based study revealed increased risks of various HM associated with postoperative BC treatment. The added benefit of chemotherapy and radiation therapy should take into consideration these long-term complications.<\/jats:p>","DOI":"10.3390\/cancers11101463","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T05:58:33Z","timestamp":1569823113000},"page":"1463","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-7759","authenticated-orcid":false,"given":"Marie Joelle","family":"Jabagi","sequence":"first","affiliation":[{"name":"EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-7439","authenticated-orcid":false,"given":"Anthony","family":"Goncalves","sequence":"additional","affiliation":[{"name":"Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Vey","sequence":"additional","affiliation":[{"name":"Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thien","family":"Le Tri","sequence":"additional","affiliation":[{"name":"EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France"},{"name":"Versailles Saint-Quentin-en-Yvelines University, 78000 Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7646-3667","authenticated-orcid":false,"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[{"name":"EPI-PHARE (French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM)), 143 Boulevard Anatole, 93200 Saint-Denis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of Chemotherapy for Solid Tumors with Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","article-title":"Risk of marrow neoplasms after adjuvant breast cancer therapy: The national comprehensive cancer network experience","volume":"33","author":"Wolff","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-009-0376-3","article-title":"Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study","volume":"118","author":"Martin","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdn530","article-title":"Acute myeloid leukemia after breast cancer: A population-based comparison with hematological malignancies and other cancers","volume":"20","author":"Beadle","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.23966","article-title":"Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias","volume":"90","author":"Fianchi","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1309\/AJCPYWC6AQC7BAVJ","article-title":"Therapy-Related Acute Lymphoblastic Leukemia Without 11q23 Abnormality: Report of Six Cases and a Literature Review","volume":"133","author":"Chen","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/1055-9965.EPI-06-1069","article-title":"Non-Hodgkin lymphoma secondary to cancer chemotherapy","volume":"16","author":"Krishnan","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3324\/haematol.2018.193599","article-title":"Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/bmt.2015.8","article-title":"Therapy-related ALL: Cytogenetic features and hematopoietic cell transplantation outcome","volume":"50","author":"Palmer","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/cncr.26735","article-title":"Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis","volume":"118","author":"Abdulwahab","year":"2012","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e187147","DOI":"10.1001\/jamanetworkopen.2018.7147","article-title":"Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France","volume":"2","author":"Jabagi","year":"2019","journal-title":"JAMA Netw. Open."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients with Inflammatory Bowel Disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.2017.21269","article-title":"Association of Hysteroscopic vs Laparoscopic Sterilization with Procedural, Gynecological, and Medical Outcomes","volume":"319","author":"Bouillon","year":"2018","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast Cancer Treatment: A Review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"j5913","DOI":"10.1136\/bmj.j5913","article-title":"Rethinking neoadjuvant chemotherapy for breast cancer","volume":"360","author":"Vaidya","year":"2018","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"McCullagh, P., and Nelder, J.A. (1989). Generalized Linear Models, CRC Press. [2nd ed.].","DOI":"10.1007\/978-1-4899-3242-6"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Suter, M.B., and Pagani, O. (2018). Should age impact breast cancer management in young women? Fine tuning of treatment guidelines. Ther. Adv. Med. Oncol., 10.","DOI":"10.1177\/1758835918776923"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: When genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nrc1749","article-title":"Mechanisms of therapy-related carcinogenesis","volume":"5","author":"Allan","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/leu.2015.122","article-title":"Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment","volume":"30","author":"Sevcikova","year":"2016","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","article-title":"Therapy-related myeloid neoplasms","volume":"23","author":"Leone","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kaplan, H.G., Malmgren, J.A., and Atwood, M.K. (2011). Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: A registry cohort analysis 1990\u20132005. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-260"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/10428194.2015.1040013","article-title":"Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy","volume":"57","author":"Kelleher","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood.V87.9.3625.bloodjournal8793625","article-title":"Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin\u2019s disease: Long-term analysis of risk factors and outcome","volume":"87","author":"Mauch","year":"1996","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3109\/10428194.2012.753543","article-title":"Risk of non-Hodgkin lymphoma after radiotherapy for solid cancers","volume":"54","author":"Kim","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study","volume":"33","author":"Medeiros","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1038\/sj.onc.1207896","article-title":"The cancer epidemiology of radiation","volume":"23","author":"Wakeford","year":"2004","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/jnci\/djq346","article-title":"Cancer risks after radiation exposure in middle age","volume":"102","author":"Shuryak","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.breast.2005.11.007","article-title":"Increased risk of acute myeloid leukaemia after treatment for breast cancer","volume":"15","author":"Renella","year":"2006","journal-title":"Breast"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ajh.23605","article-title":"Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia","volume":"89","author":"Ornstein","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.leukres.2015.09.011","article-title":"Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis","volume":"39","author":"Giri","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1038\/bcj.2017.81","article-title":"Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance","volume":"7","author":"Rosenberg","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated with Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/10\/1463\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:49Z","timestamp":1760189149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/10\/1463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,29]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["cancers11101463"],"URL":"https:\/\/doi.org\/10.3390\/cancers11101463","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,29]]}}}